Navigating Pitfalls in Opioid-induced Constipation (OIC): A Patient-focused Strategy

Please Log In or Register to continue.

Release Date: November 30, 2016
Expiration Date: November 30, 2017

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Opioid-induced constipation (OIC) is one of the most frequently occurring side effects of opioid treatment in patients with chronic non-cancer pain. Symptoms of OIC can significantly decrease patients’ quality of life and are sometimes more distressing than the underlying pain being treated. Until recently, lifestyle changes and laxatives were the primary treatment available for cases of OIC, now new agents specifically targeting the problem have become available to address this unmet need.

In this case-based activity, you will meet Sara who has made a follow-up appointment with you to discuss her progress with the opioid treatment you have recently prescribed her. Your task is to help her comfortably address the physical problems she says she is having related to her opioid therapy, and make the appropriate assessment based on the information provided by Sara and determine the best course of action.

This clinical simulation platform will offer a learning environment where your choices determine your path. An expert faculty mentor will provide content-specific commentary on your choices and help guide you to the correct diagnosis and optimal treatment plan.

Target Audience

This activity is designed for primary care physicians, pain management specialists, pharmacists, and associated multidisciplinary clinicians who treat patients being prescribed opioids who may experience opioid-induced constipation.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify patient presentations and clinical strategies for identifying those patients who are at risk of, or have developed, OIC as a consequence of opioid analgesics
  • Compare and contrast the new and emerging treatments for OIC, differentiating between mechanisms of action, benefits, risks, and side-effect profiles


Navigating Pitfalls in OIC: A Patient-focused Strategy – Jeffrey A. Gudin, MD

Instructions for Participation and Credit

This activity is eligible for credit through November 30, 2017. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Jeffrey A. Gudin, MD
Pain Management and Palliative Care
Englewood Hospital and Medical Center
Englewood, New Jersey

Dr. Jeff Gudin received his medical degree from Albany Medical College in Albany, New York. He completed his residency in anesthesiology at the Yale University School of Medicine and his fellowship at The Yale Center for Pain Management. While in New Haven, he also trained in addiction medicine and directed a substance abuse treatment center. For the last 15 years, Dr. Gudin has been the Director of Pain Management and Palliative Care at Englewood Hospital and Medical Center, a Mt. Sinai University School of Medicine teaching affiliate in New Jersey, where he is also a Clinical Instructor in Anesthesiology. He remains active in teaching and research, and has lectured internationally on a variety of topics in pain management, palliative care, and addiction medicine.

Dr. Gudin is board certified in pain management, anesthesiology, addiction medicine, and hospice and palliative medicine. In addition, he is a medical acupuncturist and a New Jersey State Representative for the American Academy of Pain Medicine. Dr. Gudin has dedicated his career to promoting education in pain management. He attends and has presented at the American Pain Society, American Academy of Pain Management, American Academy of Physical Medicine and Rehabilitation, as well as many other national venues. He serves as a consultant to state medical boards on challenging cases, as well as to industry on novel analgesic products and risk management associated with opioids. He has presented annually at the AAPM Safe Opioid Prescribing Course.

Dr. Gudin is recognized nationally as a leader in pain management. He is an experienced researcher, consultant, speaker, and speaker trainer. He has collaborated with numerous initiatives to enhance responsible prescribing and the safe use of opioid pain medications.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-124-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Jeffrey Gudin has received honoraria related to speakers’ bureau activities from AstraZeneca, Depomed, Inc., Endo Pharmaceuticals Inc., Insys Therapeutics, Inc., Iroko Pharmaceuticals, LLC, Kaleo, Inc., Purdue Pharma L.P., and TEVA Pharmaceutical LTD, as well as consultant fees from Daiichi Sankyo, Inc., Insys Therapeutics, Inc., Kéri Pharma Group, Quest Diagnostics, and Salix Pharmaceuticals, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Physician Payments, Sunshine Act

MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from AstraZeneca.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.